Kymera officer plans $1.3M stock sale from options

Kymera Therapeutics officer Jeremy Chadwick filed a Rule 144 notice to sell 10,879 shares acquired via stock option exercises, following prior 10b5-1 sales in June 2026.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) is the issuer for which officer Jeremy Chadwick has filed a notice of proposed sale of common stock under Rule 144. The notice covers 10,879 shares of common stock to be sold on or after September 2, 2026, through Morgan Stanley Smith Barney, with the shares being acquired via exercise of stock options and sold for cash over the next three months.

In the prior three months, Chadwick reported additional Rule 144 sales of Kymera common stock, including 12,500 shares for $1,222,072.50 on June 23, 2026, 5,510 shares for $499,646.80 on June 18, 2026, and 48,883 shares for $4,410,837.77 on June 17, 2026, each identified as 10b5-1 sales.

Key Figures

Shares proposed for sale: 10,879 shares Proposed sale value: $1,295,144.95 Recent 10b5-1 sale June 23, 2026: 12,500 shares for $1,222,072.50 +2 more

5 metrics

Shares proposed for sale 10,879 shares Common stock to be sold under Rule 144 beginning on or after September 2, 2026

Proposed sale value $1,295,144.95 Aggregate market value listed for 10,879 shares in the new Rule 144 notice

Recent 10b5-1 sale June 23, 2026 12,500 shares for $1,222,072.50 Common stock sale by Jeremy Chadwick under a 10b5-1 plan

Recent 10b5-1 sale June 18, 2026 5,510 shares for $499,646.80 Common stock sale by Jeremy Chadwick under a 10b5-1 plan

Recent 10b5-1 sale June 17, 2026 48,883 shares for $4,410,837.77 Common stock sale by Jeremy Chadwick under a 10b5-1 plan

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for JEREMY CHADWICK 500 North Beacon Street"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/02/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Kymera Therapeutics (KYMR)?

The filing discloses that officer Jeremy Chadwick intends to sell 10,879 shares of Kymera common stock under Rule 144, with the shares to be acquired via exercise of stock options and sold for cash over the next three months starting September 2, 2026.

How many Kymera Therapeutics (KYMR) shares is Jeremy Chadwick planning to sell in this notice?

Jeremy Chadwick plans to sell 10,879 shares of Kymera Therapeutics common stock. The shares are to be received upon the exercise of stock options and then sold for cash under Rule 144, beginning on or after September 2, 2026.

What is the estimated value of the Kymera (KYMR) shares in the new Form 144 sale?

The notice lists an aggregate market value of $1,295,144.95 for the 10,879 shares of Kymera common stock proposed to be sold under Rule 144, based on the information provided in the securities information section.

What Kymera Therapeutics (KYMR) stock sales has Jeremy Chadwick made in the past three months?

Over the past three months, Jeremy Chadwick reported 10b5-1 sales of Kymera common stock: 12,500 shares for $1,222,072.50 on June 23, 2026, 5,510 shares for $499,646.80 on June 18, 2026, and 48,883 shares for $4,410,837.77 on June 17, 2026.

How will the Kymera (KYMR) shares in this Form 144 be acquired before sale?

The shares will be acquired through the exercise of stock options. The remarks state that the securities to be sold were and will be received upon option exercises over the next three months, with the dates of acquisition and payment matching the dates of exercise and sale.

Is the Kymera (KYMR) Form 144 sale tied to a trading plan?

The new 10,879-share proposed sale is disclosed as an exercise of stock options and cash sale under Rule 144. The filing also lists prior 10b5-1 sales in June 2026 but does not label the new proposed sale itself as a 10b5-1 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:32 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:32 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001388406
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KYMERA THERAPEUTICS, INC.
SEC File Number	001-39460
Address of Issuer	500 North Beacon Street, 4th Floor Watertown MASSACHUSETTS 02472
Phone	8572855300
Name of Person for Whose Account the Securities are To Be Sold	JEREMY CHADWICK
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10879	1295144.95	83150618	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Exercise of Stock Options	Issuer			10879	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JEREMY CHADWICK 500 North Beacon Street, 4th Floor Watertown MA 02472	Common	06/23/2026	12500	1222072.50
10b5-1 Sales for JEREMY CHADWICK 500 North Beacon Street, 4th Floor Watertown MA 02472	Common	06/18/2026	5510	499646.80
10b5-1 Sales for JEREMY CHADWICK 500 North Beacon Street, 4th Floor Watertown MA 02472	Common	06/17/2026	48883	4410837.77

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeremy Chadwick
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)